In a previous Phase I/Ib study, a correlation between improved outcomes in AML patients with high levels of the MDM2 protein has been found, thus concluding that MDM2 protein expression could be an useful biomarker to identify patients who might benefit from RG7388-based therapy (Reis et al., 2016). Here, MDM2 is linked to acute myeloid leukemia.